Synthes and Eli Lilly Sign Development and Collaboration Agreement

Synthes, Inc. and Eli Lilly and Company LLY today announced the signing of an exclusive worldwide collaboration agreement to address the needs of patients who are cared for by orthopedic surgeons, including those with osteoporosis and those with bone fractures. The agreement allows for the joint development and licensing of early stage compounds from Lilly to Synthes for use within orthopedic trauma, spine, craniomaxillofacial and reconstructive areas. These compounds have pre-clinical and in some cases clinical data packages and have the potential to aid in the local treatment and regeneration of the skeleton. The two companies will jointly develop site-specific osteoinductive products based on Synthes' biomaterials combined with Lilly's biologics or pharmaceuticals.